WO2000003980A1 - DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF - Google Patents

DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF Download PDF

Info

Publication number
WO2000003980A1
WO2000003980A1 PCT/JP1999/003798 JP9903798W WO0003980A1 WO 2000003980 A1 WO2000003980 A1 WO 2000003980A1 JP 9903798 W JP9903798 W JP 9903798W WO 0003980 A1 WO0003980 A1 WO 0003980A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
thia
prostaglandin
substituted phenyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1999/003798
Other languages
English (en)
French (fr)
Inventor
Toru Maruyama
Shuichi Ohuchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99929831A priority Critical patent/EP1097922B1/en
Priority to JP2000560089A priority patent/JP3174563B2/ja
Priority to US09/720,675 priority patent/US6462081B1/en
Priority to AT99929831T priority patent/ATE291013T1/de
Priority to DE69924258T priority patent/DE69924258T2/de
Priority to NZ509293A priority patent/NZ509293A/en
Priority to CA002336952A priority patent/CA2336952C/en
Priority to AU46518/99A priority patent/AU763668B2/en
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to HU0204170A priority patent/HUP0204170A3/hu
Priority to DK99929831T priority patent/DK1097922T3/da
Priority to BRPI9912813-6A priority patent/BR9912813B1/pt
Publication of WO2000003980A1 publication Critical patent/WO2000003980A1/ja
Priority to NO20010213A priority patent/NO327781B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/JP1999/003798 1998-07-15 1999-07-14 DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF Ceased WO2000003980A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002336952A CA2336952C (en) 1998-07-15 1999-07-14 5-thia-.omega.-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
US09/720,675 US6462081B1 (en) 1998-07-15 1999-07-14 5-thia-ω-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient
AT99929831T ATE291013T1 (de) 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
DE69924258T DE69924258T2 (de) 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl-prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
NZ509293A NZ509293A (en) 1998-07-15 1999-07-14 5-Thia-omega-substituted phenyl-prostaglandin E derivatives
AU46518/99A AU763668B2 (en) 1998-07-15 1999-07-14 5-Thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient
HU0204170A HUP0204170A3 (en) 1998-07-15 1999-07-14 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
EP99929831A EP1097922B1 (en) 1998-07-15 1999-07-14 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
JP2000560089A JP3174563B2 (ja) 1998-07-15 1999-07-14 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
DK99929831T DK1097922T3 (da) 1998-07-15 1999-07-14 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel
BRPI9912813-6A BR9912813B1 (pt) 1998-07-15 1999-07-14 derivados de fenil-prostaglandina e 5-tia-omega-substituìdos, processo para a produção dos mesmos, bem como composição e uso dos referidos derivados.
NO20010213A NO327781B1 (no) 1998-07-15 2001-01-12 5-tia-ω-substituerte fenyl-prostaglandin E-derivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/200752 1998-07-15
JP20075298 1998-07-15

Publications (1)

Publication Number Publication Date
WO2000003980A1 true WO2000003980A1 (fr) 2000-01-27

Family

ID=16429595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/003798 Ceased WO2000003980A1 (fr) 1998-07-15 1999-07-14 DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF

Country Status (21)

Country Link
US (1) US6462081B1 (ja)
EP (1) EP1097922B1 (ja)
JP (1) JP3174563B2 (ja)
KR (1) KR100598660B1 (ja)
CN (1) CN1173945C (ja)
AT (1) ATE291013T1 (ja)
AU (1) AU763668B2 (ja)
BR (1) BR9912813B1 (ja)
CA (1) CA2336952C (ja)
DE (1) DE69924258T2 (ja)
DK (1) DK1097922T3 (ja)
ES (1) ES2239448T3 (ja)
HU (1) HUP0204170A3 (ja)
NO (1) NO327781B1 (ja)
NZ (1) NZ509293A (ja)
PT (1) PT1097922E (ja)
RU (1) RU2220135C2 (ja)
TR (1) TR200100623T2 (ja)
TW (1) TWI249520B (ja)
WO (1) WO2000003980A1 (ja)
ZA (1) ZA200100295B (ja)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024800A1 (en) * 1999-10-07 2001-04-12 Ono Pharmaceutical Co., Ltd. Erection insufficiency remedies
WO2001037877A1 (en) * 1999-11-24 2001-05-31 Ono Pharmaceutical Co., Ltd. Remedies for diseases in association with decrease in bone mass
WO2002047669A1 (en) * 2000-12-14 2002-06-20 Glaxo Group Limited Use of ep4 receptor agonists for treating neuropathic pain
WO2003009872A1 (fr) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Medicaments contenant un agoniste de ep4 en tant que principe actif destines aux maladies associees a une perte de la masse osseuse
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
JP2005537225A (ja) * 2002-04-17 2005-12-08 メディカル リサーチ カウンシル 子宮の病態治療のためのＦＰレセプターアンタゴニスト又はＰＧＦ２αアンタゴニスト
JP2005537235A (ja) * 2002-06-06 2005-12-08 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体作動薬、組成物及びその方法
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
WO2006016689A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
EP1132086B1 (en) * 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US7074942B2 (en) 1999-08-04 2006-07-11 The Procter & Gamble Company 2-decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
US7166631B2 (en) 2001-02-09 2007-01-23 Glaxo Group Limited Benzo[f]isoindole derivatives with affinity to the EP4 receptor
WO2007088190A1 (en) 2006-02-03 2007-08-09 Glaxo Group Limited Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists
US7276531B2 (en) 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
WO2008050848A1 (en) 2006-10-26 2008-05-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
US7388029B2 (en) 2000-03-31 2008-06-17 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2008071736A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
US7407987B2 (en) 2000-03-31 2008-08-05 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
JP2008533158A (ja) * 2005-03-17 2008-08-21 アラーガン、インコーポレイテッド 炎症性腸疾患の処置
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
US7465755B2 (en) 2003-07-18 2008-12-16 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
WO2009056582A1 (en) 2007-11-02 2009-05-07 Glaxo Group Limited Novel compounds
WO2010096123A2 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US20120136011A1 (en) * 2010-07-30 2012-05-31 Allergan, Inc. Compounds and methods for skin repair
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
WO2014144781A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US10112920B2 (en) 2008-07-25 2018-10-30 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10174017B2 (en) 2009-05-01 2019-01-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10472327B2 (en) 2007-01-10 2019-11-12 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
AU2227401A (en) * 2000-01-05 2001-07-16 Ono Pharmaceutical Co. Ltd. 5-thia-omega-(substituted phenyl)-prostaglandin e alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the activeingredient
US6586462B2 (en) * 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
RU2296122C2 (ru) * 2001-07-16 2007-03-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пирролидона в качестве простаноидных агонистов и фармацевтическая композиция
JP2003078830A (ja) * 2001-09-03 2003-03-14 Sony Corp デジタル放送受信装置および通信情報伝送方法
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
BR0308493A (pt) * 2002-03-18 2005-01-11 Pfizer Prod Inc Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular
JP3678366B2 (ja) 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
RU2335490C2 (ru) * 2003-02-07 2008-10-10 Оно Фармасьютикал Ко., Лтд. Соединения карбоновой кислоты, фармацевтическая композиция на их основе, способ лечения и применение
WO2005102389A2 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7511168B2 (en) * 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP2016527006A (ja) 2013-07-19 2016-09-08 ケイマン ケミカル カンパニー， インコーポレーテッド 骨成長を促進するための方法、システム、及び組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6379870A (ja) * 1986-09-24 1988-04-09 Teijin Ltd プロスタグランジンｅ↓１誘導体の製造法
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JPH07233144A (ja) * 1993-12-29 1995-09-05 Taisho Pharmaceut Co Ltd プロスタグランジン誘導体、その塩およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
EP0386901A1 (en) * 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. Novel 5-hetero-6-oxo-PGE derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6379870A (ja) * 1986-09-24 1988-04-09 Teijin Ltd プロスタグランジンｅ↓１誘導体の製造法
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JPH07233144A (ja) * 1993-12-29 1995-09-05 Taisho Pharmaceut Co Ltd プロスタグランジン誘導体、その塩およびその使用

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US7115659B2 (en) 1999-08-04 2006-10-03 The Procter & Gamble Company Method of treating a condition by administering a prostaglandin derivative
US7074942B2 (en) 1999-08-04 2006-07-11 The Procter & Gamble Company 2-decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6710081B1 (en) 1999-10-07 2004-03-23 Ono Pharmaceutical Co., Ltd. Erection insufficiency remedies
WO2001024800A1 (en) * 1999-10-07 2001-04-12 Ono Pharmaceutical Co., Ltd. Erection insufficiency remedies
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
WO2001037877A1 (en) * 1999-11-24 2001-05-31 Ono Pharmaceutical Co., Ltd. Remedies for diseases in association with decrease in bone mass
EP1132086B1 (en) * 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US7388029B2 (en) 2000-03-31 2008-06-17 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7407987B2 (en) 2000-03-31 2008-08-05 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9675539B2 (en) 2000-03-31 2017-06-13 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2002047669A1 (en) * 2000-12-14 2002-06-20 Glaxo Group Limited Use of ep4 receptor agonists for treating neuropathic pain
US7732622B2 (en) 2001-02-09 2010-06-08 Glaxo Group Limited Naphthalene derivatives
US7166631B2 (en) 2001-02-09 2007-01-23 Glaxo Group Limited Benzo[f]isoindole derivatives with affinity to the EP4 receptor
EP2255829A3 (en) * 2001-07-23 2012-03-28 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
WO2003009872A1 (fr) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Medicaments contenant un agoniste de ep4 en tant que principe actif destines aux maladies associees a une perte de la masse osseuse
US7608637B2 (en) * 2001-07-23 2009-10-27 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient
US8207223B2 (en) 2001-07-23 2012-06-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
RU2303451C2 (ru) * 2001-07-23 2007-07-27 Оно Фармасьютикал Ко., Лтд. Фармацевтические композиции для лечения заболеваний, связанных с уменьшением костной массы, включающие агонист ер4 в качестве активного ингредиента
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
EP2255829A2 (en) 2001-07-23 2010-12-01 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
KR100826866B1 (ko) * 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
RU2315746C2 (ru) * 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
US7786161B2 (en) 2001-08-09 2010-08-31 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
US7491748B2 (en) 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
JP2005537225A (ja) * 2002-04-17 2005-12-08 メディカル リサーチ カウンシル 子宮の病態治療のためのＦＰレセプターアンタゴニスト又はＰＧＦ２αアンタゴニスト
JP4766875B2 (ja) * 2002-06-06 2011-09-07 メルク フロスト カナダ リミテツド Ｅｐ４受容体作動薬、組成物及びその方法
JP2005537235A (ja) * 2002-06-06 2005-12-08 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体作動薬、組成物及びその方法
US8642630B2 (en) 2002-10-10 2014-02-04 Ono Pharmaceutical Co., Ltd. Endogeneous repair factor production accelerators
EP2465537A1 (en) 2002-10-10 2012-06-20 ONO Pharmaceutical Co., Ltd. Microspheres comprising ONO-1301
US7547715B2 (en) 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
WO2004032965A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
JP4497320B2 (ja) * 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
US8436026B2 (en) 2002-10-10 2013-05-07 Ono Pharmaceutical Co., Ltd. Endogeneous repair factor production promoters
JPWO2004032965A1 (ja) * 2002-10-10 2006-02-09 小野薬品工業株式会社 内因性修復因子産生促進剤
US7276531B2 (en) 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7465755B2 (en) 2003-07-18 2008-12-16 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7858610B2 (en) 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
JP4888775B2 (ja) * 2004-08-10 2012-02-29 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
WO2006016689A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JPWO2006016689A1 (ja) * 2004-08-10 2008-05-01 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
JP2008533158A (ja) * 2005-03-17 2008-08-21 アラーガン、インコーポレイテッド 炎症性腸疾患の処置
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
EP2457897A1 (en) 2006-02-03 2012-05-30 Glaxo Group Limited Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists
WO2007088190A1 (en) 2006-02-03 2007-08-09 Glaxo Group Limited Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists
WO2008050848A1 (en) 2006-10-26 2008-05-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
WO2008071736A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
US10472327B2 (en) 2007-01-10 2019-11-12 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10899714B2 (en) 2007-01-10 2021-01-26 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
WO2009056582A1 (en) 2007-11-02 2009-05-07 Glaxo Group Limited Novel compounds
US11021456B2 (en) 2008-07-25 2021-06-01 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10112920B2 (en) 2008-07-25 2018-10-30 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10532993B2 (en) 2008-07-25 2020-01-14 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10882840B2 (en) 2008-07-25 2021-01-05 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010096123A2 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
US10654844B2 (en) 2009-05-01 2020-05-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US11028081B2 (en) 2009-05-01 2021-06-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US11618748B2 (en) 2009-05-01 2023-04-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10174017B2 (en) 2009-05-01 2019-01-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10316029B2 (en) 2009-05-01 2019-06-11 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US20120136011A1 (en) * 2010-07-30 2012-05-31 Allergan, Inc. Compounds and methods for skin repair
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
US10588901B2 (en) 2013-03-15 2020-03-17 Aerie Pharmaceuticals, Inc. Combination therapy
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
US9993470B2 (en) 2013-03-15 2018-06-12 Aerie Pharmaceuticals, Inc. Combination therapy
EP3461484A1 (en) 2013-03-15 2019-04-03 Aerie Pharmaceuticals, Inc. Combination therapy
EP4335507A2 (en) 2013-03-15 2024-03-13 Aerie Pharmaceuticals, Inc. Combination therapy
EP4218759A2 (en) 2013-03-15 2023-08-02 Aerie Pharmaceuticals, Inc. Combination therapy
US9931336B2 (en) 2013-03-15 2018-04-03 Aerie Pharmaceuticals, Inc. Combination therapy
US9849122B2 (en) 2013-03-15 2017-12-26 Aerie Pharmaceuticals, Inc. Combination therapy
EP3811943A1 (en) 2013-03-15 2021-04-28 Aerie Pharmaceuticals, Inc. Compound for use in the treatment of ocular disorders
WO2014144781A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US11020385B2 (en) 2013-03-15 2021-06-01 Aerie Pharmaceuticals, Inc. Combination therapy
US10568878B2 (en) 2013-03-15 2020-02-25 Aerie Pharmaceuticals, Inc. Combination therapy
US11185538B2 (en) 2013-03-15 2021-11-30 Aerie Pharmaceuticals, Inc. Compositions for treating glaucoma or reducing intraocular pressure
US11197853B2 (en) 2013-03-15 2021-12-14 Aerie Pharmaceuticals, Inc. Combination therapy
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11590123B2 (en) 2016-08-31 2023-02-28 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11707460B2 (en) 2016-08-31 2023-07-25 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11312700B2 (en) 2017-03-31 2022-04-26 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12018012B2 (en) 2017-03-31 2024-06-25 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11891376B2 (en) 2018-09-14 2024-02-06 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Also Published As

Publication number Publication date
US6462081B1 (en) 2002-10-08
NO20010213L (no) 2001-03-15
DE69924258D1 (de) 2005-04-21
AU4651899A (en) 2000-02-07
JP3174563B2 (ja) 2001-06-11
NO327781B1 (no) 2009-09-21
PT1097922E (pt) 2005-06-30
EP1097922A1 (en) 2001-05-09
NO20010213D0 (no) 2001-01-12
ES2239448T3 (es) 2005-09-16
HUP0204170A2 (hu) 2003-04-28
TWI249520B (en) 2006-02-21
EP1097922A4 (en) 2003-02-12
EP1097922B1 (en) 2005-03-16
AU763668B2 (en) 2003-07-31
KR20010053386A (ko) 2001-06-25
DK1097922T3 (da) 2005-05-30
CN1312796A (zh) 2001-09-12
CA2336952C (en) 2009-09-15
DE69924258T2 (de) 2006-01-26
CA2336952A1 (en) 2000-01-27
ATE291013T1 (de) 2005-04-15
NZ509293A (en) 2003-05-30
BR9912813A (pt) 2001-05-02
CN1173945C (zh) 2004-11-03
RU2220135C2 (ru) 2003-12-27
HUP0204170A3 (en) 2005-03-29
KR100598660B1 (ko) 2006-07-13
TR200100623T2 (tr) 2001-06-21
ZA200100295B (en) 2002-07-10
BR9912813B1 (pt) 2010-11-30

Similar Documents

Publication Publication Date Title
WO2000003980A1 (fr) DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF
WO2002024647A1 (en) Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
CA2368347A1 (en) Glucokinase activators
CA2448602A1 (en) Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
CA2415966A1 (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
CA2040982A1 (en) N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, their preparation and use
DE68906609D1 (de) Dopamin-vorlaeufer.
DK0615754T3 (da) Faste flupertinholdige orale administrationsformer med kontrolleret frigivelse af den aktive forbindelse
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
CA2072233A1 (en) Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
WO2004022699A3 (en) Liquid stable composition of oxazaphosphorine with mesna
NO20010454D0 (no) Anvendelse av derivater av camptotécin med en redusert gastrointestinal toksisitet
HRP20020238A2 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
US4894365A (en) Combinations of FU and BVU as anti-adenocarcinoma agents
AU636178B2 (en) 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives
AU5631180A (en) Tetracyclic indole derivatives
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
CA2445262A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
JP2006503049A5 (ja)
JP4426654B2 (ja) 免疫調節用医薬組成物
US3821381A (en) Method of treatment
JPH09124593A5 (ja)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809703.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN HU JP KR MX NO NZ RU TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09720675

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017000093

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 46518/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2336952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001/00295

Country of ref document: ZA

Ref document number: 509293

Country of ref document: NZ

Ref document number: 200100295

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000507

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999929831

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/00623

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999929831

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017000093

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 46518/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999929831

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017000093

Country of ref document: KR